These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25521720)

  • 1. Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay.
    Tran HTT; Sørensen B; Bjørnsen S; Pripp AH; Tjønnfjord GE; Andre Holme P
    Haemophilia; 2015 Mar; 21(2):275-283. PubMed ID: 25521720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors.
    Tran HT; Sørensen B; Rea CJ; Bjørnsen S; Ueland T; Pripp AH; Tjønnfjord GE; Holme PA
    Haemophilia; 2014 May; 20(3):369-75. PubMed ID: 24251535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
    Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
    Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.
    Furukawa S; Nogami K; Shimonishi N; Nakajima Y; Matsumoto T; Shima M
    Br J Haematol; 2020 Sep; 190(5):727-735. PubMed ID: 32162680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.
    Ogiwara K; Nogami K; Matsumoto T; Shima M
    Int J Hematol; 2014; 99(5):577-87. PubMed ID: 24687919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry.
    Furukawa S; Nogami K; Ogiwara K; Yada K; Minami H; Shima M
    J Thromb Haemost; 2015 Jul; 13(7):1279-84. PubMed ID: 25903848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
    Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G
    Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience.
    Holmström M; Tran HT; Holme PA
    Haemophilia; 2012 Jul; 18(4):544-9. PubMed ID: 22348384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.
    Fernández-Bello I; Stenmo C; Butta N; Lind V; Ezban M; Jiménez-Yuste V
    Haemophilia; 2017 Nov; 23(6):868-876. PubMed ID: 28851065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
    Qi X; Zhao Y; Li K; Fan L; Hua B
    Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A.
    van Veen JJ; Gatt A; Bowyer AE; Cooper PC; Kitchen S; Makris M
    Thromb Res; 2009 Apr; 123(6):895-901. PubMed ID: 19012951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction.
    Livnat T; Sehgal A; Qian K; Van Nguyen H; Madigan K; Sorensen B; Kenet G
    Blood Cells Mol Dis; 2020 May; 82():102416. PubMed ID: 32066048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
    Klintman J; Astermark J; Berntorp E
    Br J Haematol; 2010 Nov; 151(4):381-6. PubMed ID: 20977448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is some better than none: are TEG and TGA profiles different in severe FVIII-deficient patients with inhibitors?
    Salinas V; Carmona R; Mohammed BM; Martin EJ; Brophy DF; Young G
    Haemophilia; 2015 May; 21(3):398-404. PubMed ID: 25495850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
    Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
    Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
    Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
    Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two laboratory assays in monitoring the efficacy of different prophylaxis regimens for severe haemophilia.
    Djunic I; Dopsaj V; Miljic P; Savic N; Milic N; Mitrovic M; Suvajdzic-Vukovic N; Tomin D; Elezovic I
    Clin Lab; 2014; 60(8):1325-31. PubMed ID: 25185418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.